Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
International Journal of Oncology|May 20, 2021
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survivalMaëva Chauvin, Véronique Garambois, Sylvie Choblet, et al.
Neoplasia (New York, N.Y.)|March 13, 2013
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylationYassamine Lazrek, Olivier Dubreuil, Véronique Garambois, et al.
Cancer Letters|June 24, 2018
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancerCharline Ogier, Pierre-Emmanuel Colombo, Corinne Bousquet, et al.
International Journal of Radiation Oncology, Biology, Physics|January 22, 2020
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer CellsLaura Bourillon, Sylvain Demontoy, Alexis Lenglet, et al.
Mabs|April 20, 2021
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer modelsEmilia Rabia, Véronique Garambois, Julie Hubert, et al.
Cancer Research|April 17, 2019
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (<i>ATR</i>) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal CancerEve Combès, Augusto F Andrade, Diego Tosi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 22, 2023
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumorsKarl Bordeau, Morgan Michalet, Valérie Dorion, et al.
Leukemia|December 15, 2019
The therapeutic effectiveness of <sup>177</sup>Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrestAlexandre Pichard, Sara Marcatili, Jihad Karam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian CancerEmmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger RadioimmunotherapyRiad Ladjohounlou, Catherine Lozza, Alexandre Pichard, et al.
Pageof 7